Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04368039

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.

Recruiting

Interested in participating?

Request Info

Key information

Age range

15 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Harding Hospital

Columbus, Ohio, 43210, United States

Location status: Recruiting

Location contact

Nicholas Breitborde, PhD

CONTACT

[email protected]

614-685-6052

About this study

Functional deficits in prefrontal, limbic, and temporal regions of the brain are well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may contribute to such pathology, and effective functioning of mitochondrial activity in the brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy may improve symptoms in individuals with psychosis. This small pilot study will test this hypothesis.

Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2). Participants will be blinded to what condition they receive. Both conditions will be delivered via nasal cannula connected to oxygen concentrators at five liters per minute (lpm), and participants will be instructed to complete the intervention overnight while sleeping. At the end of the 4 week period, all individuals will receive an additional 4 weeks of unblinded (i.e., "open label") nightly normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment; (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.
  • Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory .
  • No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.
  • Ages 15-35
  • Non-smoker for past six months
  • Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale
  • The American Association for Respiratory Care notes that "no absolute contraindications to oxygen therapy exist when indications [for oxygen therapy] are present."

Treatment and study plan

normobaric oxygen

Device

40% FiO2 for 4 weeks

PLACEBO

Device

21% FiO2 for 4 weeks

Primary outcomes

  1. Change from baseline in cognitive functioning

    Time frame: 4 weeks

    Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).

  2. Change from baseline in quality of life

    Time frame: 4 weeks

    Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.

  3. Change from baseline in social functioning

    Time frame: 4 weeks

    Change in scores on the Global Functioning: Social Scale. Scores on this measure range from 1-10 with higher scores indicating greater social functioning

  4. Change from baseline in role functioning

    Time frame: 4 weeks

    Change in scores on the Global Functioning: Role Scale. Scores on this measure range from 1-10 with higher scores indicative of greater role functioning.

  5. Change from baseline in health-related quality of life

    Time frame: 4 weeks

    Change in scores on the RAND 36-Item Health Survey.

Secondary outcomes

  1. Change from baseline in suicidality

    Time frame: 4 weeks

    Change in occurrence in suicidal thoughts or behaviors as assessed using the Columbia Suicide Severity Rating Scale. This is a categorical rating scale that identifies the presence or absence of specific levels of severity of suicidal ideation and behavior.

  2. Change from baseline in substance use severity

    Time frame: 4 weeks

    Change in scores on the HABITS scale. This scale assesses the absolute values of use of specific substances (e.g., number of cigarettes smoked)

  3. Change from baseline in service utilization

    Time frame: 4 weeks

    Change in scores on the Modified Service Use and Resources Form for Schizophrenia

  4. Change in Sleep

    Time frame: 4 weeks

    Change in scores on the Pittsburgh Sleep Quality Index.

  5. Change from baseline in medication adherence

    Time frame: 4 weeks

    Change in scores on the Medication Adherence rating Scale. Scores on this scale range from 0-10 with higher scores indicative of greater medication adherence.

Study contacts

Contact information is provided by the study sponsor or research team.

Nicholas Breitborde, PhD

CONTACT

[email protected]

(614) 685-6052

Sponsors and collaborators

Lead sponsor

Nicholas Breitborde

Other

Registry information

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Apr 29, 2020
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.